Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liposome bupivacaine vs ropivacaine for postoperative pain after thoracoscopic lobectomy
ChiCTR2400081225Phase 4Not yet recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of bupivacaine in acute postoperative pain (2 arms), sponsored by Zhejiang Cancer Hospital. Primary endpoint: Incidence of acute pain within 72 hours after thoracoscopic lobectomy. Planned start Feb 2024; status: not yet recruiting.
02
Drugs
bupivacaine
03
Conditions
acute postoperative pain
Beyond the preview
Go deeper on ChiCTR2400081225.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400081225.